Among key examples already underway: proton therapy at Lancaster General Health and Virtua Health in New Jersey, both set to open this year sub-specialty surgery consultation at outpatient sites and Penn Medicine’s regional hospitals and telemedical options for genetic counseling and CAR T cell therapy and bone marrow transplant evaluation and education. Vonderheide will build on the development of pathways to ensure that, amid the increasingly complex landscape of cancer care and research, patients across the entire health system are able to access leading-edge Penn Medicine care no matter where they live. Vonderheide will also continue in his roles as Vice President for Cancer Programs in the University of Pennsylvania Health System and Vice Dean for Cancer Programs in Penn’s Perelman School of Medicine. Under his leadership, the ACC has also launched new cancer home care and telemedicine programs, as well as initiatives that drove improvements in germline genetic testing, cancer screenings, and clinical trial participation by minority patients. Vonderheide has been appointed to a second five-year term as director of the Abramson Cancer Center (ACC) at the University of Pennsylvania, following a highly successful tenure that saw 17 FDA approvals in oncology for therapies based on studies led or co-led by ACC investigators, high-impact basic and translational research discoveries, expansion of radiation oncology services to new sites across the Philadelphia region, and development of new methods for live tumor imaging during surgeries. Robert Vonderheide Appointed to Second Five-Year Term as Director of the Abramson Cancer Center
0 kommentar(er)
